Renishaw invests in D3 Technologies Limited
9 July 2007
Renishaw is pleased to announce it has acquired a 75% interest in D3 Technologies Limited, D3, now Renishaw Diagnostics Ltd., a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy (SERS) and to develop SERS for molecular diagnostics and trace detection.
Renishaw's investment in D3 will comprise cash of £1.85 million and instrumentation, with a combined value of approximately £5m over the next 5 years. Part of the investment has been used by D3 to purchase for £850,000 the business and assets of the analytical business unit ("ABU") operated by Mesophotonics Limited, a spinout company from the University of Southampton. The ABU develops and manufactures substrates used in SERS applications. Combining the SERS technology and biochemistry expertise of the University of Strathclyde with the Klarite® substrate technology of Mesophotonics ABU offers a broad range of product opportunities to exploit in the growing healthcare diagnostics and forensic markets.
As a leading supplier of Raman instrumentation Renishaw has a vested interest in the furtherance of Raman spectroscopy and its applications into new and developing markets.
Enquiries: Caterina Netti, Head of Operations and Technology (+44 141 5577900)
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.